Operating Income (Loss) in USD of AVADEL PHARMACEUTICALS PLC from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
AVADEL PHARMACEUTICALS PLC quarterly/annual Operating Income (Loss) history and change rate from 2010 to Q3 2025.
  • AVADEL PHARMACEUTICALS PLC Operating Income (Loss) for the quarter ending 30 Sep 2025 was $1.94M.
  • AVADEL PHARMACEUTICALS PLC Operating Income (Loss) for the twelve months ending 30 Sep 2025 was $4.52M.
  • AVADEL PHARMACEUTICALS PLC annual Operating Income (Loss) for 2024 was -$42.4M, a 69.2% increase from 2023.
  • AVADEL PHARMACEUTICALS PLC annual Operating Income (Loss) for 2023 was -$138M, a 39.9% decline from 2022.
  • AVADEL PHARMACEUTICALS PLC annual Operating Income (Loss) for 2022 was -$98.6M, a 15.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $4.52M $1.94M +$2.26M 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 $2.26M $8.88M +$21.6M 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$19.4M -$3M +$23M +88.5% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$42.4M -$3.3M +$21.6M +86.8% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025
Q3 2024 -$64M -$327K +$34.8M +99.1% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025
Q2 2024 -$98.8M -$12.7M +$36.8M +74.3% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$136M -$26M +$2.26M +8% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$138M -$24.9M -$1.86M -8.08% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 -$136M -$35.1M -$18.2M -107% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$118M -$49.5M -$19.6M -65.5% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$98.2M -$28.3M +$328K +1.15% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 -$98.6M -$23M +$98K +0.42% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025
Q3 2022 -$98.7M -$17M +$8.7M +33.9% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$107M -$29.9M -$8M -36.5% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$99.4M -$28.6M -$13.8M -93.3% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 -$85.5M -$23.1M -$8.88M -62.2% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024
Q3 2021 -$76.7M -$25.7M -$12M -87.4% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$64.7M -$21.9M -$62.2M -154% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$2.5M -$14.8M -$8.31M -128% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 $5.82M -$14.3M -$6.91M -94.1% 01 Oct 2020 31 Dec 2020 10-K 16 Mar 2022
Q3 2020 $12.7M -$13.7M -$9.55M -230% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 $22.3M $40.3M +$44.7M 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$22.4M -$6.5M +$1.67M +20.4% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$24.1M -$7.35M +$68.1M +90.3% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2022
Q3 2019 -$92.2M -$4.15M +$9.95M +70.6% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$102M -$4.45M -$1.67M -59.8% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$100M -$8.17M +$4.46M +35.3% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 -$105M -$75.4M -$71.3M -1749% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 -$33.6M -$14.1M -$40.2M -154% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $6.63M -$2.79M -$36.9M -108% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $43.5M -$12.6M -$46M -138% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019
Q4 2017 $89.5M -$4.08M -$21.1M -124% 01 Oct 2017 31 Dec 2017 10-K 16 Mar 2020
Q3 2017 $111M $26.1M +$42.3M 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018
Q2 2017 $68.3M $34.1M +$45.7M 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 $22.7M $33.3M +$27.6M +485% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018
Q4 2016 -$4.97M $17.1M -$60.3M -78% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2019
Q3 2016 $55.4M -$16.2M -$1.7M -11.8% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $57.1M -$11.5M -$9.17M -387% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 $66.2M $5.7M -$4.51M -44.2% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017
Q4 2015 $70.8M $77.4M +$111M 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2018
Q3 2015 -$39.8M -$14.5M +$2.33M +13.9% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$42.2M -$2.37M +$17M +87.8% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016
Q1 2015 -$59.2M $10.2M +$34.4M 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$93.7M -$33.2M -$30.5M -1142% 01 Oct 2014 31 Dec 2014 10-K 28 Mar 2017
Q3 2014 -$63.1M -$16.8M -$10M -147% 01 Jul 2014 30 Sep 2014 6-K 17 Nov 2014
Q2 2014 -$53.1M -$19.4M +$15M +43.6% 01 Apr 2014 30 Jun 2014 6-K 31 Dec 2015
Q1 2014 -$68.1M -$24.2M -$14.4M -146% 01 Jan 2014 31 Mar 2014 6-K 10 Jul 2015
Q4 2013 -$53.7M -$2.67M -$5.65M -190% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016
Q3 2013 -$48M -$6.8M -$286K -4.39% 01 Jul 2013 30 Sep 2013 6-K 17 Nov 2014
Q2 2013 -$47.8M -$34.4M -$28M -443% 01 Apr 2013 30 Jun 2013 6-K 08 Aug 2014
Q1 2013 -$19.7M -$9.85M -$9.81M -21315% 01 Jan 2013 31 Mar 2013 6-K 08 Jul 2014
Q4 2012 -$9.91M $2.98M 01 Oct 2012 31 Dec 2012 20-F 01 Oct 2015
Q3 2012 -$6.52M 01 Jul 2012 30 Sep 2012 6-K 15 Jan 2014
Q2 2012 -$6.33M -$2.68M -73.2% 01 Apr 2012 30 Jun 2012 6-K 06 Dec 2013
Q1 2012 -$46K +$4.85M +99.1% 01 Jan 2012 31 Mar 2012 6-K 13 Sep 2012
Q2 2011 -$3.66M 01 Apr 2011 30 Jun 2011 6-K 14 Dec 2012
Q1 2011 -$4.89M 01 Jan 2011 31 Mar 2011 6-K 13 Sep 2012

AVADEL PHARMACEUTICALS PLC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$42.4M +$95.5M +69.2% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025
2023 -$138M -$39.3M -39.9% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025
2022 -$98.6M -$13M -15.2% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025
2021 -$85.5M -$91.4M -1571% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024
2020 $5.82M +$29.9M 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022
2019 -$24.1M +$80.8M +77% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2022
2018 -$105M -$194M -217% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 $89.5M +$94.5M 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020
2016 -$4.97M -$75.7M -107% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2019
2015 $70.8M +$164M 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$93.7M -$40M -74.4% 01 Jan 2014 31 Dec 2014 10-K 28 Mar 2017
2013 -$53.7M -$43.8M -442% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016
2012 -$9.91M -$330K -3.44% 01 Jan 2012 31 Dec 2012 20-F 01 Oct 2015
2011 -$9.58M +$257K +2.61% 01 Jan 2011 31 Dec 2011 20-F/A 30 Apr 2014
2010 -$9.84M 01 Jan 2010 31 Dec 2010 20-F 30 Apr 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.